Does the LDL receptor play a role in the risk of developing type 2 diabetes?

JAMA - Journal of the American Medical Association

Volumn 313, Issue 10, 2015, Pages 1016-1017

  Preiss, David ^a   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

APOB GENE; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE MUTATION; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HMGCR GENE; HUMAN; LDLR GENE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PCSK9 GENE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; COMPLICATION; FEMALE; MALE;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE;

EID: 84924386507     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1275     Document Type: Editorial

References (14)

1. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes. Lancet. 2010;375(9716): 735-742.
2. Preiss D, Seshasai SR,Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA. 2011;305 (24):2556-2564.
3. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight [published online September 24, 2014]. Lancet. doi:10.1016/S0140- 6736(14)61183-1.
4. Hindy G, Rukh G, Almgren P, Ericson U, Melander O, Orho-Melander M. Causal effect of decreased LDL cholesterol and increased blood pressure on higher incidence of type 2 diabetes by Mendelian randomization in the Malmö Diet and Cancer Study. Diabetologia. 2014;57:S67.
5. Do R, Stitziel NO,Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102-106.
6. Benn M,Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population. J Clin Endocrinol Metab. 2012;97(11):3956-3964.
7. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251): 165-168.
8. Vohl MC, Gaudet D, Moorjani S, et al. Comparison of the effect of 2 low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest. 1997;27(5):366-373.
9. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. doi:10.1001/jama.2015.1206.
10. Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124(5):555-562.
11. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212.
12. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statinmyopathy. J Physiol. 2009;587(Pt 1):219-230.
13. NakataM, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4). Diabetologia. 2006;49(8): 1881-1892.
14. Preiss D, Packard CJ. Emerging therapeutic approaches to treat dyslipidemia. Curr Cardiol Rep. 2014;16(7):506.